Peptides DB
Research-centric peptide and protocol reference hub
Study 7 of 7Argireline literatureJournal of cosmetic dermatology · Observational2026

Transdermal Delivery of Botulinum Toxin for the Management of Oily and Acne-Prone Skin Using TDA Technology.

Transdermal delivery of botulinum toxin may reduce sebum levels and improve skin clarity in oily and acne-prone skin, but the study's small size and observational design warrant caution in interpreting these findings.

Read at Journal of cosmetic dermatologyAdd to compare

Where it sits

this study against the rest of the argireline corpus
1
Preclinical
6
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study evaluated the clinical efficacy and safety of transdermal delivery of botulinum toxin using TDA technology in 19 participants aged 20-50. The study reported a statistically significant reduction in sebum levels and improvements in self-reported skin clarity and satisfaction. No adverse events were reported.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Journal of cosmetic dermatology supplied them

<h4>Background</h4>Intradermal botulinum toxin injections have been shown to reduce sebaceous gland activity and improve skin texture in patients with oily and acne-prone skin. However, needle-based application is associated with discomfort and potential side effects.<h4>Objective</h4>To evaluate the clinical efficacy and safety of transdermal delivery of botulinum toxin (150 kDa) using Transdermal Application (TDA) technology for the treatment of oily and acne-prone skin.<h4>Methods</h4>In this single-center observational study, 19 participants (aged 20-50) underwent treatment with the DERMADROP MED TDA device according to the BIOBOTOX protocol. Objective assessments included Sebumeter measurements and 2D/3D skin imaging. Subjective evaluation was conducted using validated patient-reported outcome measures (OSIS, OSSAS) at baseline, 2 weeks, and 4 weeks posttreatment.<h4>Results</h4>A statistically significant reduction in sebum levels was observed, accompanied by notable improvements in self-reported skin clarity and satisfaction. No adverse events were reported.<h4>Conclusion</h4>Transdermal application of botulinum toxin using TDA-based DERMADROP MED technology is a safe, well-tolerated, and effective noninvasive treatment modality for reducing sebaceous activity and improving the appearance of oily and acne-prone skin.

Elsewhere in the Argireline corpus

DCosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulation.International journal of cosmetic science · 2026 · 861 μmol TE/g antioxidant activity for Reishi extract.DCosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulation.PubMed · 2026 · 861 μmol TE/g antioxidant activity for Reishi extract.DSemantic Scholar search for ArgirelineSemanticScholar · 2010DINDIVIDUAL ARTICLE: Real-World Clinical Experience With a Neuro-Peptide Serum in Combination With Botulinum Toxin Type-A Injections.PubMed · 2024BAcetyl Dipeptide-31 Amide: A Novel Cosmetic Anti-Inflammatory Peptide That Demonstrates Anti-Aging, Firming, and Lifting Benefits.PubMed · 2024 · Not reported in abstract.HumanCBAK and ARG Have Moisturizing, Anti-Inflammatory, Antioxidant, and Antioxidant Bioactivities, in the Zebrafish Model.PubMed · 2025 · Not reported in abstract.Animal